With support from NFL owner Jeffrey Lurie, Icelandic biotech closes Series A for oral Alzheimer's drug

Max Gelman

Senior Editor

A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral treatments for Alzheimer’s disease and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With support from NFL owner Jeffrey Lurie, Icelandic biotech closes Series A for oral Alzheimer's drug

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

With sup­port from NFL own­er Jef­frey Lurie, Ice­landic biotech clos­es Se­ries A for oral Alzheimer's drug

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With support from NFL owner Jeffrey Lurie, Icelandic biotech closes Series A for oral Alzheimer's drug